Metforal (Metformin Hydrochloride)

Metformin hydrochloride activates AMP‑activated protein kinase (AMPK), which reduces hepatic glucose production, decreases intestinal glucose absorption, and enhances peripheral insulin sensitivity. These combined effects lower fasting and post‑prandial blood glucose levels without stimulating insulin secretion.

The appropriate dose of Metforal is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of metformin during pregnancy or lactation should be evaluated by a qualified healthcare provider. While metformin is sometimes used in gestational diabetes, the decision depends on maternal‑fetal risk assessment. Breastfeeding mothers should discuss potential exposure with their doctor.

To request Metforal, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metforal (metformin) belongs to the Biguanide class and is often first‑line therapy for type 2 diabetes because of its efficacy, low risk of hypoglycaemia, and favourable impact on weight. Compared with sulfonylureas or insulin, metformin does not cause weight gain and has a different safety profile, making it suitable for many patients.

Metforal should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and excessive heat. Keep the product out of reach of children and avoid exposure to direct sunlight.

Metforal is taken orally, usually with meals to minimise gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

The most serious risk is lactic acidosis, a rare but potentially fatal condition characterized by elevated blood lactate levels. Signs include muscle pain, rapid breathing, abdominal discomfort, and feeling unusually weak. Prompt medical attention is required if these symptoms occur.

Metforal is contraindicated in patients with severe renal impairment, acute or chronic metabolic acidosis, known hypersensitivity to metformin, and those who have received iodinated contrast media within the previous 48 hours. Clinicians should also exercise caution in patients with hepatic disease, heart failure, or a history of lactic acidosis.